Reversal Reaction in A Borderline Lepromatous Leprosy Patient after COVID-19 Vaccine: Prevention or Risks?

Authors

  • Rusmawardiana Department of Dermatology and and Venereology, Faculty of Medicine Sriwijaya University, Dr. Mohammad Hoesin General Hospital, Palembang, South Sumatra, Indonesia
  • Fifa Argentina Department of Dermatology and and Venereology, Faculty of Medicine Sriwijaya University, Dr. Mohammad Hoesin General Hospital, Palembang, South Sumatra, Indonesia
  • Raden Pamudji Department of Dermatology and and Venereology, Faculty of Medicine Sriwijaya University, Dr. Mohammad Hoesin General Hospital, Palembang, South Sumatra, Indonesia
  • Odelia Jovita Jusuf Fantoni Dermatology and Venereology Department, Sriwijaya University, Dr. Moh. General Hospital, Palembang, Indonesia

DOI:

https://doi.org/10.66344/jpad.v32i3.1953

Abstract

Reversal reaction in leprosy is an immunologically mediated response due to alteration of cell-mediated immunity associated in leprosy spectrum. In COVID-19 pandemic era, leprosy patient is susceptible to the infection. According to guideline, vaccination should be given to leprosy patients. This case reported a 33-year-old male with reversal reaction after COVID-19 vaccination. On examination, patient had erythematous plaque of the face, trunk and extremities, also multiple ulcers of the trunk and extremities. Treatment was commenced immediately with prednisone and second vaccination was delayed. Within our follow-up, marked improvement were obtained after 6 weeks.

References

1. Lastória JC, de Abreu MAMM. Leprosy: Review of the epidemiological, clinical, and etiopathogenic aspects - Part 1. An Bras Dermatol. 2014;89(2):205-18.

2. Kahawita IP. Leprosy Care in the Era of COVID-19. Nepal J Dermatol Venereol Leprol. 2022;20(1):4-11.

3. Silva da Paz W, do Ros ario Souza M, ebora dos Santos Tavares D, elia Ribeiro de Jesus A, Dantas dos Santos A, Feliciano do Carmo R, et al. Impact of the COVID-19 pandemic on the diagnosis of leprosy in Brazil: An ecological and population-based study. Lancet Reg Health Am. 2022;9:100181.

4. Aponso S, Hoou LC, Wei YY, Salahuddin SA, Yit PJ. Multibacillary leprosy unmasked by COVID-19 vaccination. JAAD Case Rep. 2022;19:87-9.

5. Rathod S, Suneetha S, Narang T, Bhardwaj A, Gupta SK, Kamoji SG, et al. Management of leprosy in the context of COVID-19 pandemic. Indian Dermatol Online J. 2020;11(3):345-8.

6. Bilik L, Demir B, Cicek D. Leprosy Reactions. In: Ribon W, editor. Hansen’s Disease - The Forgotten and Neglected Disease. 1st ed. London: IntechOpen; 2019. p. 81-91.

7. World Health Organization. WHO epidemiological record - Global leprosy (Hansen disease) update, 2019: time to step-up prevention initiatives. 2020.

8. World Health Organization. WHO epidemiological record - Global leprosy (Hansen disease) update, 2020: impact of COVID-19 on global leprosy control. 2021.

9. Cerqueira SRPS, Deps PD, Cunha DV, Bezerra NVF, Barroso DH, Pinheiro ABS, et al. The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19: A prospective real-world cohort study. PLOS Negl Trop Dis. 2021;15(7):1-13.

10. Teijaro JR, Farber DL. COVID-19 vaccines: Modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195-7.

11. Sandre MK, Poenaru SM, Boggild AK. Erythema Nodosum Leprosum Triggered by Antecedent Influenza Vaccine and Respiratory Tract Infection: A Case Report. J Cutan Med Surg. 2019;23(1):114-6.

12. Kar HK, Chauhan A. Leprosy Reactions: Pathogenesis and Clinical Features. In: Kumar B, Kar HK, editors. IAL Textbook of Leprosy. 2nd ed. New Delhi: Jaypee; 2017. p. 416-40.

13. World Health Organization. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19 [Internet]. 2021 May. Available from: https://www.who.int/publications/i/item/WHO-2019-

14. Escobar A, Reyes-López FE, Acevedo ML, Alonso-Palomares L, Valiente-Echeverría F, Soto-Rifo R, et al. Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group. Front Immunol. 2022;12:1-8.

15. Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6(1):1-13.

16. Marques NP, Marques NCT, Cardozo IM, Martelli DRB, de Lucena EG, Oliveira EA, et al. Impact of the coronavirus disease 2019 on the diagnoses of hansen’s disease in Brazil. Rev Soc Bras Med Trop. 2021;54:1-4.

Downloads

Published

27.08.2022

Issue

Vol. 32 No. 3 (2022): July - September

Section

Case Reports

License

Copyright (c) 2022 Odelia Jovita Jusuf Fantoni

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.

How to Cite

1.
Reversal Reaction in A Borderline Lepromatous Leprosy Patient after COVID-19 Vaccine: Prevention or Risks?. J Pak Assoc Dermatol [Internet]. 2022 Aug. 27 [cited 2026 Aug. 25];32(3):609-12. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1953